GH at a glance
Guardant Health, Inc. (GH, SEC CIK 1576280) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Guardant Health, Inc. (GH) reported revenue of $982.0 million (up 32.9% from FY2024) and a net loss of $416.3 million. Diluted EPS was -$3.32.
- As of June 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Guardant Health, Inc. (GH) shares worth $9.3 billion in 13F-HR filings.
- In the last 90 days, GH insiders reported 0 open-market purchases ($0) and 26 open-market sales ($30.7M) on Form 4, a net sale of $30.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $982.0M
- +32.9% vs prior year
- Insiders · 90 days
- 0 buys · 26 sells
- Net −$30.7M
- 13F holders
- 35 funds
- $9.3B · −1 vs prior quarter
- Latest 8-K
- Jul 30, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Precision oncology company providing liquid biopsy and blood-based tests for cancer detection, treatment selection, and monitoring across all disease stages
- New emphasis: Expanded Guardant Reveal test for late-stage therapy response monitoring; Shield test granted FDA Breakthrough Device status for multi-cancer detection
- Strategic shift: Migration of key tests (Guardant360 Liquid, Reveal) to proprietary Smart Platform leveraging multiomic data and AI for enhanced sensitivity and insights
- Quantitative highlight: Global expansion includes launch of Guardant360 CDx testing at Policlinico Gemelli in Italy (Dec 2025) and reimbursement approval in Japan (July 2023)
- Noteworthy fact: Shield blood test is first FDA-approved and Medicare-covered primary colorectal cancer screening blood test, now included in NCCN screening guidelines
Risk Factors
- Medicare reimbursement 10%+ of revenue in 2025, 2024, 2023; risk from CMS regulation changes hindering direct billing
- Geopolitical and economic instability, including wars, terrorism, pandemics, may disrupt business and affect operating results
- Limited laboratory capacity and unautomated processes constrain scaling; facility expansion and equipment procurement delays possible
- Competitor Roche-owned Foundation Medicine, Exact Sciences, and others increasing M&A and development efforts in liquid biopsy and genomic profiling
- Revenue concentration: Top 5 biopharmaceutical customers contributed 11% of total revenue in 2025, risking material financial impact if lost
Management Discussion & Analysis
- Revenue $982.0M in 2025 vs $739.0M in 2024, up $243M or 32.9% YoY
- Net loss improved to $416.3M in 2025 from $436.4M in 2024, margin not explicitly stated
- Best segment: Oncology tests for clinical customers, supported by expanded Medicare coverage and FDA approvals
- Worst segment: Not explicitly stated; overall net losses indicate ongoing high operating expenses
- Cash & equivalents $1.3B as of Dec 31, 2025; capital allocation details on buybacks/dividends not disclosed
- Increased R&D spending on new product innovation and large clinical studies (e.g., Shield post-approval SOLAR study)
- Management outlook highlights focus on international expansion, payer coverage improvements, and reimbursement risks
AI summary of the GH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $335.0M, up 44% YoY from $232.1M
- Best segment Screening revenue $52.9M, up 257% YoY; volume approximately 66,000 vs 16,000
- Oncology revenue $219.1M, up 38% YoY; volume approximately 104,000 vs 64,000
- Net loss $120.1M vs $99.9M YoY; operating loss $129.1M vs $106.4M
- Cash, cash equivalents, and restricted cash approximately $1.2B as of June 30, 2026
Risk Factors
- No material changes to previously disclosed risk factors during Q2 fiscal 2026
- Carried-forward business risk: risks could materially adversely affect business, financial condition, cash flows, results, and stock price
- Carried-forward healthcare-industry risk: disclosed uncertainties may affect future operating results and financial condition
- Carried-forward forecasting risk: historical performance is not a reliable indicator of future performance
AI summary of the GH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Guardant Health reported fiscal quarter results for quarter ended June 30, 2026
- Full financial results furnished in Exhibit 99.1, requiring investor review for operating metrics and outlook
Item EX-99.1: Item EX-99.1
- Q2 revenue $335.0M, up 44%, led by Oncology $219.1M and Screening $52.9M
- Shield screening tests reached 66,000, up from 16,000, supporting rapid Screening adoption
Item 5.07: Submission of Matters to a Vote of Security Holders
- Ian Clark and Manuel Hidalgo Medina re-elected as directors, with 37.9M and 26.5M votes withheld respectively
- Executive compensation advisory vote failed, signaling shareholder dissatisfaction despite 98.2M votes supporting pay practices
Item 2.02: Results of Operations and Financial Condition
- Guardant Health reported financial results for the quarter ended March 31, 2026
- Full results and management commentary furnished in Exhibit 99.1
AI summaries of GH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GH
Don't miss the next GH filing
- Alerts as it files. A push when GH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GH, by share count.
- Ask anything. An AI agent that reads every GH filing and answers with sources.
GH alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Talasaz AmirAli | M | Oct 1, 2026 | 23,997 | - |
| Talasaz AmirAli | M | Oct 1, 2026 | 9,716 | - |
| Talasaz AmirAli | F | Oct 1, 2026 | 17,087 | $174.75 |
| Talasaz AmirAli | M | Oct 1, 2026 | 23,997 | - |
| Talasaz AmirAli | M | Oct 1, 2026 | 9,716 | - |
| Eltoukhy Helmy | M | Oct 1, 2026 | 23,997 | - |
| Eltoukhy Helmy | M | Oct 1, 2026 | 9,716 | - |
| Eltoukhy Helmy | F | Oct 1, 2026 | 17,087 | $174.75 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $739.0M | $982.0M |
| Operating Income | - | -$443.6M | -$437.2M |
| Net Income | -$479.4M | -$436.4M | -$416.3M |
| Op. Margin | - | -60.0% | -44.5% |
| Net Margin | - | -59.0% | -42.4% |
| Balance Sheet | |||
| Total Assets | - | $1.5B | $2.0B |
| Equity | $158.7M | -$139.6M | -$99.3M |
| ROE | -302.1% | 312.5% | 419.2% |
| Per Share | |||
| EPS | $-4.28 | $-3.56 | $-3.32 |
| Cash Flow | |||
| Operating CF | - | -$239.9M | -$184.8M |
| CapEx | $20.5M | $35.1M | $48.3M |
Source: XBRL data in Guardant Health, Inc. (GH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate GH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 35 | $9.27B |
| Q1 2026 | 36 | $6.00B |
| Q4 2025 | 33 | $5.61B |
| Q3 2025 | 32 | $3.21B |
| Q2 2025 | 33 | $2.74B |
| Q1 2025 | 29 | $1.48B |
| Q4 2024 | 22 | $854.7M |
| Q3 2024 | 20 | $312.8M |
- Ameriprise Financial+1.74M (+123%)
- FMR LLC (Fidelity)+1.37M (+33%)
- D.E. Shaw & Co+828.2K (+194%)
- Millennium Management+701.1K (+76%)
- Citadel Advisors LLC+673.6K (+87%)
- BlackRock−3.93M (-34%)
- Goldman Sachs Group−659.9K (-15%)
- State Street Corp−621.1K (-22%)
- Invesco Ltd−516.7K (-10%)
- Two Sigma Investments−510.2K (-12%)
- Allstate+8.9K
- Renaissance Technologies LLC−337.6K
- Marex Group plc−3.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 240 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
- NTRA · Natera IncServices-Medical Laboratories
GH SEC filings: frequently asked questions
Are GH insiders buying or selling?
In the last 90 days, Guardant Health, Inc. (GH) officers, directors and 10% owners reported no open-market purchases and 26 open-market sales worth $30.7 million by 10 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold GH stock?
As of June 30, 2026, the largest Guardant Health, Inc. (GH) holders among the 13F filers tracked by SignalX were BlackRock ($1.1 billion), T. Rowe Price Group ($977.4 million), Vanguard Capital Management LLC ($863.6 million), FMR LLC (Fidelity) ($823.4 million), Vanguard Portfolio Management LLC ($817.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was GH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Guardant Health, Inc. (GH) reported revenue of $982.0 million (up 32.9% from FY2024) and a net loss of $416.3 million. Diluted EPS was -$3.32. The figures come from the XBRL data in the 10-K.
What are the main risks in GH's latest 10-K?
In the 10-K filed February 19, 2026, Guardant Health, Inc. (GH) flagged: Medicare reimbursement 10%+ of revenue in 2025, 2024, 2023; risk from CMS regulation changes hindering direct billing. Geopolitical and economic instability, including wars, terrorism, pandemics, may disrupt business and affect operating results. (AI summary of the Risk Factors section.)
What did GH report in its latest 8-K?
Guardant Health, Inc. (GH) filed an 8-K on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Guardant Health reported fiscal quarter results for quarter ended June 30, 2026.
What are the latest GH SEC filings?
Guardant Health, Inc. (GH) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and a Form 4 insider filing on October 2, 2026.
What is GH's SEC CIK number?
Guardant Health, Inc. (GH)'s SEC Central Index Key (CIK) is 1576280. EDGAR lists every GH filing under that number.
Ask anything about GH
The research agent reads GH's filings, financials, insider trades and 13F holders, then answers with sources.